{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:39:13Z","timestamp":1758098353066,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ijtb.2020.11.004","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T02:04:04Z","timestamp":1604714644000},"page":"412-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Case reports of chronic myeloid leukemia and tuberculosis: Is imatinib the link between the two?"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-9064","authenticated-orcid":false,"given":"Shailendra Prasad","family":"verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil Kumar","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneel Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2020.11.004_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ijtb.2020.11.004_bib2","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits Tcell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ijtb.2020.11.004_bib3","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","article-title":"Imatinib inhibits the activation and proliferation of normal T lymphocytes in\u00a0vitro","volume":"18","author":"Cwynarski","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ijtb.2020.11.004_bib4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2003-12-4266","article-title":"Imatinib mesylate inhibits T-cell proliferation in\u00a0vitro and delayed-type hypersensitivity in\u00a0vivo","volume":"104","author":"Dietz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ijtb.2020.11.004_bib5","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.4049\/jimmunol.178.4.2028","article-title":"Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in\u00a0vivo","volume":"178","author":"Sinai","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ijtb.2020.11.004_bib6","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1086\/503917","article-title":"The risk of tuberculosis in patients with cancer","volume":"42","author":"Kamboj","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijtb.2020.11.004_bib7","first-page":"1110","article-title":"Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances","volume":"90","author":"Silva","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ijtb.2020.11.004_bib8","first-page":"976","article-title":"Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate","volume":"9","author":"Mattiuzzi","year":"2003","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ijtb.2020.11.004_bib9","first-page":"114","article-title":"Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour","volume":"44","author":"Durosinmi","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.ijtb.2020.11.004_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","article-title":"Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment","volume":"47","author":"Ikeda","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijtb.2020.11.004_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1183\/09031936.00025408","article-title":"Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia","volume":"33","author":"Daniels","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2020.11.004_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000348712","article-title":"Tuberculous and non tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor","volume":"6","author":"Agaimya","year":"2013","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ijtb.2020.11.004_bib13","first-page":"A1768","article-title":"Tuberculous lymphadenitis complicating imatinib treatment for chronic myeloid leukemia","volume":"189","author":"Yaghmour","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ijtb.2020.11.004_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2169\/internalmedicine.44.114","article-title":"Malignant Gastrointestinal Stromal Tumor of the small intestine complicated by pulmonary tuberculosis during treatment with imatinib mesylate","volume":"44","author":"Takashima","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.ijtb.2020.11.004_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","article-title":"Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells","volume":"103","author":"Appel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ijtb.2020.11.004_bib16","first-page":"762","article-title":"Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia","volume":"88","author":"Steegmann","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.ijtb.2020.11.004_bib17","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.4049\/jimmunol.178.4.2028","article-title":"Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in\u00a0vivo","volume":"178","author":"Sinai","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ijtb.2020.11.004_bib18","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","article-title":"Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections","volume":"108","author":"Mumprecht","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ijtb.2020.11.004_bib19","first-page":"1","article-title":"Challenges in diagnosis and treatment of latent tuberculosis infection","volume":"59","author":"Gupta","year":"2012","journal-title":"Indian J Tubercul"},{"issue":"1","key":"10.1016\/j.ijtb.2020.11.004_bib20","first-page":"65","article-title":"Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis","volume":"18","author":"Bhatnagar","year":"2015","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.ijtb.2020.11.004_bib21","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570720302146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570720302146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:59:50Z","timestamp":1758081590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570720302146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0019570720302146"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2020.11.004","relation":{},"ISSN":["0019-5707"],"issn-type":[{"type":"print","value":"0019-5707"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case reports of chronic myeloid leukemia and tuberculosis: Is imatinib the link between the two?","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2020.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}